Kasow Kimberly A, Leung Wing, Horwitz Edwin M, Woodard Paul, Handgretinger Rupert, Hale Gregory A
Department of Hematology/Oncology, Division of Stem Cell Transplantation, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
Pediatr Blood Cancer. 2007 Nov;49(6):869-72. doi: 10.1002/pbc.20710.
Post-transplant lymphoproliferative disease (PTLPD), due to the reactivation of Epstein-Barr virus (EBV), is a serious complication. The risk of the disorder increases with T-cell depletion methods, mismatched hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and immunosuppression. In contrast to solid organ transplantation, where EBV is typically of recipient origin, the source of the EBV in HSCT recipients is donor-derived B-lymphocytes. In this report, we describe a 15-year-old girl who underwent HSCT from her father as treatment for acute myeloid leukemia (AML). She subsequently developed disseminated PTLPD involving multiple organ and nodal sites. Her neoplastic lymphoblasts were host-derived and refractory to rituximab treatment due to lack of CD20 expression.
移植后淋巴细胞增生性疾病（PTLPD）是一种严重的并发症，由EB病毒（EBV）重新激活引起。该疾病的风险会随着T细胞清除方法、不匹配的造血干细胞移植（HSCT）、移植物抗宿主病（GVHD）和免疫抑制而增加。与实体器官移植中EBV通常来源于受者不同，HSCT受者体内的EBV来源是供体来源的B淋巴细胞。在本报告中，我们描述了一名15岁女孩，她接受了来自父亲的HSCT以治疗急性髓系白血病（AML）。随后，她发展为播散性PTLPD，累及多个器官和淋巴结部位。她的肿瘤性淋巴母细胞来源于宿主，并且由于缺乏CD20表达而对利妥昔单抗治疗无效。
